MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PIRAMAL ENTERPRISES LTD. (pharmaceuticals)
- Latest 8 Quarter Result
Piramal Healthcare Quarterly Results 
(NCHP)
Here are the latest quarterly results of Piramal Healthcare. For more details, see the Piramal Healthcare financial fact sheet and Piramal Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.
Piramal Healthcare Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 22,541 | 25,359 | 28,584 | 29,911 | 29,025 | 31,441 | 34,891 | 36,797 | |
| Other income | Rs m | 838 | 754 | 638 | 365 | 144 | 563 | 1,028 | 852 | |
| Turnover | Rs m | 23,379 | 26,113 | 29,222 | 30,276 | 29,169 | 32,004 | 35,919 | 37,649 | |
| Expenses | Rs m | 11,923 | 12,660 | 14,110 | 16,103 | 13,758 | 14,911 | 14,618 | 17,380 | |
| Gross profit | Rs m | 10,618 | 12,699 | 14,474 | 14,732 | 10,744 | 17,264 | 20,273 | 19,283 | |
| Depreciation | Rs m | 1,229 | 1,293 | 1,100 | 1,151 | 1,288 | 1,234 | 1,326 | 1,354 | |
| Interest | Rs m | 6,732 | 7,247 | 7,497 | 8,306 | 9,091 | 10,162 | 11,688 | 13,157 | |
| Profit before tax | Rs m | 3,495 | 4,912 | 6,515 | 5,640 | 510 | 6,432 | 8,287 | 5,624 | |
| Tax | Rs m | 1,021 | 1,898 | 2,118 | -33,800 | 1,810 | 1,628 | 2,930 | 2,243 | |
| Profit after tax | Rs m | 2,475 | 3,015 | 4,397 | 39,440 | -1,300 | 4,804 | 5,356 | 3,381 | |
| Gross profit margin | % | 47.1 | 50.1 | 50.6 | 49.3 | 37.0 | 54.9 | 58.1 | 52.4 | |
| Effective tax rate | % | 29.2 | 38.6 | 32.5 | -599.3 | 355.1 | 25.3 | 35.4 | 39.9 | |
| Net profit margin | % | 11.0 | 11.9 | 15.4 | 131.9 | -4.5 | 15.3 | 15.4 | 9.2 | |
| Diluted EPS | Rs | 14.3 | 17.5 | 25.5 | 228.6 | -7.5 | 27.8 | 31.0 | 19.6 | |
| Diluted EPS (TTM) | Rs | 72.7 | 72.4 | 74.5 | 285.8 | 264.0 | 274.3 | 279.9 | 70.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Piramal Healthcare 4QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: TORRENT PHARMA SHASUN PHARMA J.B.CHEMICALS WOCKHARDT PROCTER & GAMBLE HEALTH
Compare PIRAMAL ENTERPRISES With: TORRENT PHARMA SHASUN PHARMA J.B.CHEMICALS WOCKHARDT PROCTER & GAMBLE HEALTH
Compare PIRAMAL ENTERPRISES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 160 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)
Indian share markets traded on a positive note most of the day and ended higher. Gains were largely seen in the IT sector and healthcare sector, while capital goods stocks witnessed selling pressure.
Views on news
GSK PHARMA Surges by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)
Jul 15, 2019 | Updated on Jul 15, 2019GSK PHARMA share price has surged by 5% and its current market price is Rs 1,210. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 5.1%) and PIRAMAL ENTERPRISES (up 5.8%). The top losers are CAPLIN POINT and ABBOTT INDIA .
PIRAMAL ENTERPRISES Surges by 5%; BSE HEALTHCARE Index Up 0.4% (Market Updates)
Jul 15, 2019 | Updated on Jul 15, 2019PIRAMAL ENTERPRISES share price has surged by 5% and its current market price is Rs 2,052. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index are PIRAMAL ENTERPRISES (up 5.1%) and SUN PHARMA ADV. RES. (up 5.9%). The top losers are ASTRAZENECA PHARMA (down 0.1%) and IPCA LABS (down 0.1%).
PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)
Jul 9, 2019 | Updated on Jul 9, 2019Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.
PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)
Apr 30, 2019 | Updated on Apr 30, 2019For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)
Jan 30, 2019 | Updated on Jan 30, 2019For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
More Views on NewsMost Popular
I Believe this is the Best Stock to Buy Today (Profit Hunter)
Jul 3, 2019The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.
This Smallcap Stock could be the next Page Industries (Profit Hunter)
Jul 2, 2019The smallcap rebound is taking longer to play out...and that's good news as it gives you more of action time and opportunities to invest in.
The Indian Rating Agency Cleanup Has Begun and this Cheap Stock Could be the Best Bet (The 5 Minute Wrapup)
Jul 2, 2019The last time this big rating agency was as cheap and out-of-favour as it is today, the stock had corrected by 40% in six months.
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)
Jul 5, 2019Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?
More|
| |
PIRAMAL ENTERPRISES SHARE PRICE
Jul 15, 2019 (Close)
TRACK PIRAMAL ENTERPRISES
- Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PIRAMAL ENTERPRISES
PIRAMAL ENTERPRISES - ABBOTT INDIA COMPARISON
COMPARE PIRAMAL ENTERPRISES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.